In 2018–2020, the subject of this article—the new advanced hybrid closed-loop system t:slim X2TM insulin pump with Control-IQ® technology from Tandem Diabetes Care, based on a control algorithm developed at the University of Virginia, was tested in two randomized controlled trials (RCTs) comparing Control-IQ with sensor-augmented pump (SAP) therapy. This evidence concerns the gene INS and diabetes mellitus.